.png)
SummarySwitzerland is the most transparent price system in Europe about its own method and one of the least convenient to consume as data. The list of reimbursed medicines is public and searchable, the pricing rules are documented down to the reference countries and the exchange rate dates, and the whole system sits outside the European Union while using nine European countries as its yardstick.
The Spezialitätenliste is the list of medicines reimbursed by Swiss compulsory health insurance. It is maintained by the federal office of public health, which also decides admission, price and any limitation on use. The public application is at sl.bag.admin.ch, reachable on 14 September 2026.
Two price levels matter, and Switzerland names both explicitly.
The Fabrikabgabepreis, the ex-factory price. What the manufacturer receives for the product.
The Publikumspreis, the public price. What compulsory insurance pays. It is composed of the ex-factory price, the distribution share and value added tax of 2.6 percent.
That composition is stated by the authority itself, which makes Switzerland unusual: in most European countries the relationship between the published price and the manufacturer price has to be reconstructed from a margin regulation, and here it is described in plain terms on a public page.
The Swiss distribution share remunerates the logistics costs in the distribution channels, meaning pharmacies, doctors, hospitals and wholesalers. Affected medicines are assigned to distribution share groups, with products of equivalent active ingredient grouped together.
Two consequences for anyone modelling Swiss prices.
First, the distance between the ex-factory price and the public price is not a single percentage that can be applied across the assortment. It depends on the group a product sits in.
Second, because both levels are published for listed products, the distance does not need to be modelled at all in normal use. Read the level you need rather than deriving it, which is the same principle that makes Belgium and Poland comfortable to work with.
Switzerland assesses the economic viability of a medicine partly through a foreign price comparison. The reference countries are Belgium, Denmark, Germany, Finland, France, the United Kingdom, the Netherlands, Austria and Sweden.
The foreign ex-factory prices are converted into Swiss francs using exchange rates that the authority sets twice a year, on 1 January and 1 July, and publishes.
For a pricing team that combination is operationally important. A Swiss price decision depends on ex-factory levels in nine other markets at a defined conversion rate on a defined date, which means the launch sequence and price level chosen in those markets has a calculable effect in Switzerland. It also means a Swiss review can move for reasons that have nothing to do with Switzerland: a price cut in a reference country, or a currency movement between two rate settings.
Alongside the foreign comparison sits the therapeutic cross comparison, which weighs the price of a new medicine against medicines already reimbursed for the same indication. Both instruments are described on the authority's own pricing FAQ.
Every medicine on the list is reviewed every three years to check whether it still meets the conditions for inclusion, including its price. The review for 2026 begins in the authority's electronic application in January.
That cycle is worth carrying in a data model as a date rather than as background knowledge. It tells you when a price is due to be re-examined, which is a better predictor of movement than a trend line over past values.
The reimbursed range is public. Products on the list carry both an ex-factory and a public price, along with limitations on use where they apply.
The method is documented. Reference countries, exchange rate dates, review cycle, distribution share groups, tax rate. Few European systems publish that much of their own reasoning.
The list stops at reimbursement. Products outside compulsory insurance, including the freely priced over the counter range, are not governed by it. The same boundary applies in Poland, Italy and Spain, and it has to be stated in the same breath as any Swiss average.
For product master data beyond the list, including identifiers and pack attributes across the full Swiss assortment, the route is a commercial database rather than the public list. That is a licensing question, in the same category as Austria and the Netherlands rather than a technical one.
Three questions come up constantly in Swiss price work and the list answers none of them.
What was actually paid. As everywhere in Europe, the published figure is a regulated price rather than a transaction. Hospital procurement in particular runs below it.
What non listed products cost. Prices outside the reimbursed range are set freely and are not published by the authority.
How a pack maps to a foreign pack. The list is a Swiss instrument with Swiss identifiers. Cross-border matching needs an identifier layer that the list itself does not provide.
The first of those is universal, the second is shared with several EU countries, and the third is the reason Switzerland, like most markets, needs a separate identification source alongside the price source.
For a DACH product, Switzerland behaves differently from Germany and Austria in one decisive respect: the price mechanism is published in full and the ex-factory level is visible for listed products. Germany makes a negotiated figure visible in its price data, Austria keeps the manufacturer level in a licensed product directory, and Switzerland publishes both of its levels for the reimbursed range.
What the three share is the boundary at the edge of the reimbursed or listed segment, and a commercial layer beyond it. A DACH price product therefore has three different access conversations and one common gap.
For a team in Germany, France or the Netherlands, Switzerland is usually encountered in one of two ways. Either as a reference market whose price level is quoted in a board paper, or as the market that reads your own ex-factory price as one of its nine inputs.
The second relationship is the one worth understanding, because it runs in the opposite direction to intuition. A Swiss price is partly a function of decisions taken elsewhere, at a conversion rate fixed twice a year. A price reduction agreed in one of the nine reference markets travels into the Swiss assessment at the next review, whether or not anyone in Switzerland was party to it.
Most European price comparisons involve either the euro or a currency with a relatively stable relationship to it. The Swiss franc is neither, and its movements are large enough to change the ranking of Switzerland in a price comparison without any price changing.
That is the practical argument for using the authority's own published rates rather than a market rate of the day: the comparison then reproduces how the Swiss system itself values a foreign price, and the result can be checked against a published figure rather than against a data feed.
Anyone publishing a Swiss to European comparison should state three things in the same line: the price level, the exchange rate used and its date. Without all three the number cannot be reproduced.
Switzerland publishes both ends of its price chain for reimbursed medicines and explains the mechanism between them, which is more than most European systems do. The work is not in reconstructing a formula, it is in respecting three boundaries: the list covers the reimbursed range and nothing else, the distribution share is group specific rather than a flat rate, and every cross-border figure needs an exchange rate with a date attached.
Related reading: European Drug Pricing Database: how cross-border prices work and Pharma pricing Germany: how the system works, plus ex-factory price and external reference pricing in Europe.
pharmazie.com is the consolidated pharmaceutical data platform by DACON Datenbank Consulting GmbH that bundles 25+ specialist databases into a single search, exclusively for healthcare professionals. Price coverage focuses on the DACH region and a number of further EU countries, with more countries following in the coming months.
